Antiprogestogen
class of compounds
Antiprogestogens or antiprogestins, also known as progesterone antagonists or progesterone blockers, are a class of drugs which prevent progestogens like progesterone from mediating their biological effects in the body. These drugs competitively inhibit progestin at progesterone receptors, acting by blocking the progesterone receptor (PR) and/or inhibiting or suppressing progestogen production. Antiprogestogens are one of three types of sex hormone antagonists, alongside antiestrogens and antiandrogens.
Clinical applications
Antiprogestogens are used as abortifacients, emergency contraceptives, and in the treatment of uterine fibroids. They are also being studied in the treatment of breast cancer. Examples include the progesterone receptor weak partial agonist mifepristone, the selective progesterone receptor modulator (SPRM) ulipristal acetate, and the silent antagonist aglepristone. In medical abortion, mifepristone is combined with a prostaglandin (e.g., gemeprost), while ulipristal is used for emergency contraception.
Development and approval
Several hundred antiprogestogens have been developed, but only three—mifepristone, lilopristone, and onapristone—have been administered to humans. Of these, only mifepristone has been approved and introduced for clinical use.
Role and mechanism of action
Progestins, including progesterone, are vital for preparing the uterus for the implantation of a fertilized egg during the luteal phase of the menstrual cycle.
“Antiprogestogen” enters the record as class of compounds. Crown Archives preserves that source wording while asking what Antiprogestogen, class and compounds can confirm, complicate or overturn.
Why this record matters
“Antiprogestogen” is worth following because a concise public description often conceals a longer documentary argument. Here, Antiprogestogen, class and compounds provides the most credible route into that argument.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Aug 11, 2026. The linked authority identifier is Q4775139. None of the 0 selected statements returned an explicit reference.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Antiprogestogen”, its source revision and the description used here.
- Expand the search: follow Antiprogestogen primary sources, Antiprogestogen archive and Antiprogestogen research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Antiprogestogen”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Antiprogestogen” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.